Introduction: The present study aims to evaluate the risk of pancreatic cancer with
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INTRODUCTION
Over the last decade, the worldwide prevalence of type 2 diabetes mellitus (T2DM) has increased the use of incretin-based drugs [1] [2] [3] .
There are two types of incretin-based drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-IV (DPP-IV) inhibitors, both with pharmacological effects reflecting interactions between the gut and the endocrine system [4] . Currently, evidence from previous studies has illustrated the advantages of incretin-based therapies [4, 5] . GLP-1RAs (incretin mimetics)
have been shown to effectively lower blood glucose and promote weight loss with minimal hypoglycemia [5] . that the risk of pancreatic cancer was 2.9-fold greater with exenatide as compared with other anti-diabetic drugs [8] . Subsequently, the Drug Commission of German Medical Association reported similar concerns [9] . As these findings suggested that incretin mimetics increase the risk of development of pancreatic cancer, more studies began to focus on the pancreatic safety of incretin drugs. does not support a causal association between incretin-based drugs and pancreatic cancer [10] , there is no current pooled data providing direct evidence from the standpoint of evidence-based medicine to support such a conclusion.
Actually, much of the controversy was generated by Peter Butler and colleagues initially, when they speculated this association from the results of animal study involving genetically modified rats in year 2009;
followed by an adverse experience database study in 2011 and finally by an analysis of post-mortem samples in 2013 [11] [12] [13] . Therefore, in order to provide more compelling evidence, we conducted a meta-analysis by investigating all RCTs regarding any information about pancreatic cancer events during incretin-based treatments.
METHODS

Eligibility Criteria
This meta-analysis, conducted in accordance with PRISMA guidelines, included all studies reporting adverse events of pancreatic cancer with use of incretin-based therapy GLP-1RAs
and DPP-IV inhibitors compared with placebo or other non-incretin anti-diabetic drugs in patients with T2DM. Studies fulfilling the following criteria were included: (i) RCTs; (ii) studies must include an intervention group with T2DM patients treated by incretin-based therapy (studies enrolling healthy patients, ClinicalTrials.gov was also searched as it is an important resource of RCTs. All registered clinical trials from phase II to phase IV of incretin-based therapies were screened in this study. Registered trials undergoing recruiting process; not completed or those without any reporting of adverse events were excluded.
Meta-analyses previously published on investigating pancreatic safety associated with incretin drugs were also assessed for potential eligible studies.
Data Collection Process
Eligible studies were screened by two trained reviewers independently (HC and XYZ). The first reviewer (HC) obtained the eligible studies by screening titles and abstracts of publications.
As for unpublished clinical trials, basic information of study design and adverse events were primarily checked. The second reviewer (XYZ) further screened these papers using the eligibility criteria. Reference lists of relevant publications were also screened for potentially eligible studies. Discrepancies were resolved by consensus between two reviewers. Data extraction process was finished by four other reviewers (BTL, WJJ, and HYG).
Risk of Bias Across Studies
Statistical heterogeneity across the studies was assessed visually with Begger's [31] funnel plot. Furthermore, Egger test and Harbord's modified test [32] were also applied in this study.
Risk of Bias in Individual Studies
The Cochrane tool [33] for RCTs was applied for bias assessment. The following domains were evaluated for study reliability: the adequacy of randomization and concealment of allocation, blinding of participants, personnel and outcome assessors, the extent of loss to follow-up, the assessment of selective outcome reporting, and other sources of bias.
Statistical Analysis
These meta-analyses were primarily conducted with STATA (version 14.0, StataCorp, College Station, TX, USA). Statistical heterogeneity were quantified by Chi-square-based Q test and I 2 statistic (0-40%: minor; 30-60%: moderate; 50-90%: substantial; 75-100%: considerable) [34] . A fixed-effect model was used to compare pooled relative risk (RR) with related 95% confidence intervals (CIs).
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RESULTS
Description of Studies
The initial search identified a total of 5823 studies:
5549 from MEDLINE/EMBASE/ CENTRAL database and 274 from Clinicaltrial.gov. Of these, 4987 records were excluded due to irrelevant topics. 462 full-text articles and 274 clinical trials were assessed for eligibility. After excluding non-randomized and observational studies, studies with non-T2DM patients and studies with no interest of outcome, we identified 159 RCT ( Table 1 . A total of 24,462 patients had received incretin-based regimens while 23,434 had received placebo or other non-incretin-based treatments such as metformin or glimepiride.
Risk of Bias Assessment
The assessed quality of publication was of medium-to high-quality evidence and two studies (NCT01064687 and Jadzinsky 2009) [14, 25] had high risk of bias as these two studies had reported incomplete data (Fig. 2a,  b ). Begg's funnel plot (P = 0.309) suggests no evidence of heterogeneity (Fig. 3) . However, Egger's test (P = 0.019) and Harbord's modified test (P = 0.038) indicates potential heterogeneity across the studies.
Risk of Pancreatic Cancer
Within all the assessed trials, 1.59% of patients developed pancreatic cancer after exposure of incretin drugs (1.3% in those taking incretins; 1.9% in control patients). None of these studies Hence, we further conducted subgroup analyses to investigate any more specific aspect (Fig. 4a, b) .
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Effect of Study Duration
The duration of the studies varied from 24 weeks to 5 years [22, 23] . In studies with duration longer than 104 weeks, the incidence of pancreatic neoplasm with incretin-based groups was lower than with placebo or non-incretin anti-diabetic regimens (pooled RR = 0.50, 95% CI 0.29-0.87, P = 0.014). There is no significant difference in risk of pancreatic cancer among trials less than 52 weeks (pooled RR = 1.26, 95% CI 0.54-2.98, P = 0.593) and those of 52-104 weeks duration (pooled RR = 0.93, 95% CI 0.37-2.34, P = 0.879) (Fig. 5a ).
Incretin-Based Therapy Versus Placebo or Other Anti-diabetic Drugs
There are also differences among control groups within the included 24 studies. Seven trials applied incretin-matched placebo as parallel arms while 17 had non-incretin anti-diabetic drugs for control. Our results indicated decreased risk of pancreatic cancer within groups controlled by incretin-matched placebos (pooled RR = 0.55, 95% CI 0.32-0.93, P = 0.025). On the other hand, there was no increase in risk of pancreatic cancer as compared to the non-incretin anti-diabetic therapy (pooled RR = 1.04, 95% CI 0.54-2.01, P = 0.902) (Fig. 5b) .
Incretin-Based Monotherapy Versus
Combination Regimen indicate that both types of regimens did not increase risk of pancreatic cancer with regards to incretin treatment (Fig. 5c ).
Pancreatic Cancer as Principal Outcome or Not
Nineteen studies considered the incidence of pancreatic cancer to be one of the principal outcome variables (pooled RR = 1.17, 95% CI 0.62-2.19, P = 0.630). The remaining five studies investigated pancreatic cancer events (Fig. 5d ).
DISCUSSION
Our meta-analysis shows that: (1) The overall results indicated in our study were consistent with the latest FDA and EMA database assessment of pancreatic safety [13] .
Irrespective of different types of incretin-based drugs, there was no evidence of increased risk of pancreatic neoplasm associated with incretin-based treatment. This result is consistent with human and animal studies performed by the pharmaceutical companies [36, 50] . Although several observational studies have
shown an increased risk of pancreatic cancer with incretin-based drugs, these data need to be reevaluated due to the potential mechanistic questions [51, 52] . Some adjusting methods had been applied in order to reduce the confounding factors, but it is still difficult to measure such large data by a reliable methodology on the estimated population [8, 9, [53] [54] [55] [56] [57] [58] [59] [60] . Additionally, the association between diabetes mellitus itself and pancreatic cancer is also very complicated as the long-duration of T2DM is considered a risk factor for pancreatic cancer [53, 54] . Therefore, the results of observational studies need to be interpreted with caution.
As for RCTs, due to the relatively restrained and stringent inclusion criteria, potential selection bias might have existed for the enrolled patients, thus reducing the risk of pancreatic cancer [41] . Therefore, disparities between observational studies and RCTs can be ascribed to individual variations. Thus, more large-scale surveillance of both epidemiological and RCTs is needed urgently for further evaluation.
According to the current guidelines, incretin-based therapies are recommended for use as monotherapy or in combination with other anti-diabetic agents such as metformin [61] . In our study, we did not find any increased risk of pancreatic cancer with incretin-based therapies as compared to control.
Duration of the study is possibly the second influential factor for risk of pancreatic cancer.
Here, we applied two cut-out points (52 and 104 weeks) to classify the studies into three categories. Surprisingly, we detected a lower incidence of pancreatic neoplasm among those with drug intake for more than 104 weeks in incretin-based groups than those in placebo or non-incretin-based anti-diabetic therapy. This result is probably due to four high-quality large RCTs [23, 26, 29, 30] . They all applied more than 2 years follow-up periods and concluded that pancreatic cancer was uncommon and occurred more often in the placebo group, but this difference was not significant in each trial.
A recently reported international multicentre cohort study showed the same results. They reported that duration of more than 2 years of incretin use generated pooled hazard ratio close to or below unity (0.62, 0.36 to 1.07) [9, 58] , suggesting lower risk of pancreatic cancer. Although incretin drugs may cause a non-physiological condition by promoting effective beta-cells and suppressing alpha cells, the long-term regular use may promotes a new balance of pancreatic secretion and reduces the possible side effects on exocrine pancreas.
However, the longest trial in our study had a 6-year study period, but it may take up to 12 years for initiated pancreatic intraepithelial lesions to develop a parental clone which initiates infiltrating pancreatic carcinomas [62] . Thus, the current RCTs were still not long enough to detect a causal effect of incretin mimetics on pancreatic cancer.
Long-term surveillance ([10 years) of neoplasm on the exocrine pancreas is required in the future studies of incretin-based therapy.
In our study, the total incidence of pancreatic cancers was very low ( [23, 26, 29, 30, 63] . Given the long-term follow-up surveillance and large-scale of population, the pooled results may be more convincing. However, these four studies had mainly focused on investigating cardiovascular events associated with incretin-based drugs [23, 26, 29, 30] . Hence, we could not exclude the possibility of selection bias and pancreatic cancer events going unreported.
Strengths and Limitations
Our meta-analysis has several strengthens. This is the first comprehensive meta-analysis to assess all types of incretin-based therapies. 
CONCLUSION
This meta-analysis provides reassuring evidence against the hypothesis that incretin-based therapies increase the risk of pancreatic cancer. Further, subgroup analyses suggest possible beneficial effects which require direct testing in trials designed a priori to do so. Given the potential carcinogenic potency, more large-scale RCTs with longstanding surveillance of pancreatic safety are urgently warranted, whereas epidemiological studies will also continue to be needed for long-term surveillance if such RCTs are absent.
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